Stocks and Investing Stocks and Investing
Mon, April 1, 2013

Sumant Kulkarni Maintained (BIIB) at Strong Buy with Increased Target to $206 on, Apr 1st, 2013


Published on 2024-10-25 02:17:14 - WOPRAI, Sumant Kulkarni
  Print publication without navigation


Sumant Kulkarni of Canaccord Genuity, Maintained "Biogen Inc." (BIIB) at Strong Buy with Increased Target from $200 to $206 on, Apr 1st, 2013.

Sumant has made no other calls on BIIB in the last 4 months.



There are 5 other peers that have a rating on BIIB. Out of the 5 peers that are also analyzing BIIB, 2 agree with Sumant's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $166 on, Thursday, January 3rd, 2013
  • Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $141 on, Thursday, January 3rd, 2013


These are the ratings of the 3 analyists that currently disagree with Sumant


  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $188 on, Monday, March 25th, 2013
  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $200 on, Monday, March 4th, 2013
  • Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $170 on, Wednesday, February 6th, 2013
Contributing Sources